S&P 500   4,284.19 (-0.09%)
DOW   33,404.64 (-0.31%)
QQQ   360.14 (+0.52%)
AAPL   173.72 (+1.47%)
MSFT   318.77 (+0.96%)
META   305.19 (+1.66%)
GOOGL   133.22 (+1.80%)
AMZN   128.77 (+1.30%)
TSLA   248.91 (-0.52%)
NVDA   447.76 (+2.94%)
NIO   8.73 (-3.43%)
BABA   86.20 (-0.62%)
AMD   102.42 (-0.39%)
T   14.88 (-0.93%)
F   12.36 (-0.48%)
MU   67.88 (-0.22%)
CGC   0.79 (+0.77%)
GE   109.23 (-1.19%)
DIS   81.06 (+0.01%)
AMC   7.94 (-0.63%)
PFE   33.16 (-0.03%)
PYPL   59.14 (+1.16%)
NFLX   379.71 (+0.56%)
S&P 500   4,284.19 (-0.09%)
DOW   33,404.64 (-0.31%)
QQQ   360.14 (+0.52%)
AAPL   173.72 (+1.47%)
MSFT   318.77 (+0.96%)
META   305.19 (+1.66%)
GOOGL   133.22 (+1.80%)
AMZN   128.77 (+1.30%)
TSLA   248.91 (-0.52%)
NVDA   447.76 (+2.94%)
NIO   8.73 (-3.43%)
BABA   86.20 (-0.62%)
AMD   102.42 (-0.39%)
T   14.88 (-0.93%)
F   12.36 (-0.48%)
MU   67.88 (-0.22%)
CGC   0.79 (+0.77%)
GE   109.23 (-1.19%)
DIS   81.06 (+0.01%)
AMC   7.94 (-0.63%)
PFE   33.16 (-0.03%)
PYPL   59.14 (+1.16%)
NFLX   379.71 (+0.56%)
S&P 500   4,284.19 (-0.09%)
DOW   33,404.64 (-0.31%)
QQQ   360.14 (+0.52%)
AAPL   173.72 (+1.47%)
MSFT   318.77 (+0.96%)
META   305.19 (+1.66%)
GOOGL   133.22 (+1.80%)
AMZN   128.77 (+1.30%)
TSLA   248.91 (-0.52%)
NVDA   447.76 (+2.94%)
NIO   8.73 (-3.43%)
BABA   86.20 (-0.62%)
AMD   102.42 (-0.39%)
T   14.88 (-0.93%)
F   12.36 (-0.48%)
MU   67.88 (-0.22%)
CGC   0.79 (+0.77%)
GE   109.23 (-1.19%)
DIS   81.06 (+0.01%)
AMC   7.94 (-0.63%)
PFE   33.16 (-0.03%)
PYPL   59.14 (+1.16%)
NFLX   379.71 (+0.56%)
S&P 500   4,284.19 (-0.09%)
DOW   33,404.64 (-0.31%)
QQQ   360.14 (+0.52%)
AAPL   173.72 (+1.47%)
MSFT   318.77 (+0.96%)
META   305.19 (+1.66%)
GOOGL   133.22 (+1.80%)
AMZN   128.77 (+1.30%)
TSLA   248.91 (-0.52%)
NVDA   447.76 (+2.94%)
NIO   8.73 (-3.43%)
BABA   86.20 (-0.62%)
AMD   102.42 (-0.39%)
T   14.88 (-0.93%)
F   12.36 (-0.48%)
MU   67.88 (-0.22%)
CGC   0.79 (+0.77%)
GE   109.23 (-1.19%)
DIS   81.06 (+0.01%)
AMC   7.94 (-0.63%)
PFE   33.16 (-0.03%)
PYPL   59.14 (+1.16%)
NFLX   379.71 (+0.56%)

Pliant Therapeutics (PLRX) Stock Forecast, Price & News

$16.86
-0.48 (-2.77%)
(As of 10:27 AM ET)
Compare
Today's Range
$16.62
$17.59
50-Day Range
$14.58
$20.15
52-Week Range
$14.47
$36.64
Volume
126,254 shs
Average Volume
801,758 shs
Market Capitalization
$1.01 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$48.55

Pliant Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
187.9% Upside
$48.55 Price Target
Short Interest
Bearish
10.55% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.73
Upright™ Environmental Score
News Sentiment
0.60mentions of Pliant Therapeutics in the last 14 days
Based on 18 Articles This Week
Insider Trading
Selling Shares
$2.60 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.99) to ($3.55) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.42 out of 5 stars

Medical Sector

227th out of 969 stocks

Pharmaceutical Preparations Industry

86th out of 453 stocks


PLRX stock logo

About Pliant Therapeutics (NASDAQ:PLRX) Stock

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase IIa trials for idiopathic pulmonary fibrosis and primary sclerosing cholangitis. It also develops PLN-1474, a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

PLRX Price History

PLRX Stock News Headlines

How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
Pliant (PLRX) Up on Success of Mid-Stage Liver Disease Study
Pliant Therapeutics Reveals Encouraging Data From Liver Disease Trial
How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
Why Shares of Pliant Therapeutics Are Rising Tuesday
Pliant Therapeutics (NASDAQ:PLRX) Shares Down 4.7%
Stifel Nicolaus Keeps Their Buy Rating on Pliant Therapeutics (PLRX)
See More Headlines
Receive PLRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pliant Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PLRX Company Calendar

Last Earnings
8/09/2023
Today
10/02/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PLRX
Fax
N/A
Employees
155
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$48.55
High Stock Price Forecast
$63.00
Low Stock Price Forecast
$33.00
Forecasted Upside/Downside
+180.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
11 Analysts

Profitability

Net Income
$-123,320,000.00
Net Margins
-2,872.79%
Pretax Margin
-2,872.79%

Debt

Sales & Book Value

Annual Sales
$9.69 million
Book Value
$6.43 per share

Miscellaneous

Free Float
56,483,000
Market Cap
$1.04 billion
Optionable
Not Optionable
Beta
1.20
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Dr. Bernard Coulie M.B.A. (Age 57)
    M.D., MBA, Ph.D., Pres, CEO & Director
    Comp: $1.06M
  • Dr. Keith Lamont Cummings M.B.A. (Age 46)
    M.D., Chief Financial Officer
    Comp: $662.34k
  • Mr. Mike Ouimette J.D. (Age 50)
    Gen. Counsel & Corp. Sec.
    Comp: $591.05k
  • Mr. Johannes P. Hull (Age 48)
    Chief Bus. Officer
    Comp: $631.64k
  • Dr. Éric Lefebvre M.D. (Age 59)
    Chief Medical Officer
    Comp: $763.49k
  • Dr. Rik Derynck
    Scientific Founder & Member of Scientific Advisory Board
  • Mr. Dean Sheppard M.D.
    Scientific Founder & Member of Scientific Advisory Board
  • Mr. Bill DeGrado Ph.D.
    Scientific Founder & Member of Scientific Advisory Board
  • Mr. Hal Chapman M.D.
    Scientific Founder & Member of Scientific Advisory Board
  • Mr. Craig D. Muir
    Interim Chief Technology Officer













PLRX Stock - Frequently Asked Questions

Should I buy or sell Pliant Therapeutics stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pliant Therapeutics in the last year. There are currently 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PLRX shares.
View PLRX analyst ratings
or view top-rated stocks.

What is Pliant Therapeutics' stock price forecast for 2023?

11 brokers have issued 12-month price objectives for Pliant Therapeutics' shares. Their PLRX share price forecasts range from $33.00 to $63.00. On average, they predict the company's stock price to reach $48.55 in the next year. This suggests a possible upside of 180.0% from the stock's current price.
View analysts price targets for PLRX
or view top-rated stocks among Wall Street analysts.

How have PLRX shares performed in 2023?

Pliant Therapeutics' stock was trading at $19.33 at the beginning of the year. Since then, PLRX stock has decreased by 10.3% and is now trading at $17.34.
View the best growth stocks for 2023 here
.

When is Pliant Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our PLRX earnings forecast
.

How were Pliant Therapeutics' earnings last quarter?

Pliant Therapeutics, Inc. (NASDAQ:PLRX) announced its earnings results on Wednesday, August, 9th. The company reported ($0.70) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.03. The business had revenue of $0.25 million for the quarter, compared to the consensus estimate of $1.10 million. Pliant Therapeutics had a negative trailing twelve-month return on equity of 33.10% and a negative net margin of 2,872.79%.

What ETFs hold Pliant Therapeutics' stock?

ETFs with the largest weight of Pliant Therapeutics (NASDAQ:PLRX) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE).

What other stocks do shareholders of Pliant Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pliant Therapeutics investors own include Pfizer (PFE), CrowdStrike (CRWD), Trevena (TRVN), AbbVie (ABBV), Abbott Laboratories (ABT), Archer-Daniels-Midland (ADM), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD) and Applied DNA Sciences (APDN).

When did Pliant Therapeutics IPO?

(PLRX) raised $90 million in an initial public offering (IPO) on Wednesday, June 3rd 2020. The company issued 6,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Piper Sandler served as the underwriters for the IPO and Needham & Company was co-manager.

What is Pliant Therapeutics' stock symbol?

Pliant Therapeutics trades on the NASDAQ under the ticker symbol "PLRX."

How do I buy shares of Pliant Therapeutics?

Shares of PLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pliant Therapeutics' stock price today?

One share of PLRX stock can currently be purchased for approximately $17.34.

How much money does Pliant Therapeutics make?

Pliant Therapeutics (NASDAQ:PLRX) has a market capitalization of $1.04 billion and generates $9.69 million in revenue each year. The company earns $-123,320,000.00 in net income (profit) each year or ($2.74) on an earnings per share basis.

How many employees does Pliant Therapeutics have?

The company employs 155 workers across the globe.

How can I contact Pliant Therapeutics?

Pliant Therapeutics' mailing address is 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is pliantrx.com. The company can be reached via phone at 650-481-6770 or via email at ir@pliantrx.com.

This page (NASDAQ:PLRX) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -